Platelet-rich plasma

Last updated
Platelet-rich plasma
Prp-hand-rejuvenation-ama-regenerative-medicine.jpg
Platelet-rich plasma injection into the hand
MeSH D053657

Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of platelet-rich plasma protein derived from whole blood, centrifuged to remove red blood cells. Though promoted to treat an array of medical problems, evidence for benefit is mixed as of 2020, with some evidence for use in certain conditions and against use in other conditions. [1] [2] [3]

Contents

As a concentrated source of blood plasma and autologous conditioned plasma, PRP contains several different growth factors and other cytokines that can stimulate healing of soft tissue and joints. There are some indications for use in sports medicine and orthopedics (acute muscle strains, tendinopathy and muscle-fascial injuries and osteoarthritis [4] ), or dermatology (androgenic alopecia, wound healing, and skin rejuvenation) or even in proctology (fistula-in-ano [5] ). [6] For preparation of PRP, various protocols are used, with an underlying principle of concentrating platelets to 3–5 times physiological levels, then injecting this concentrate in the tissue where healing is desired. [7] Besides the use in clinical practice PRP has been utilized for various tissue engineering applications in the context of bone, cartilage, skin, and soft tissue repair. It has been reviewed to serve as a source for the "delivery of growth factors and/or cells within tissue-engineered constructs, often in combination with biomaterials". [8]

Medical use

Evidence for benefit of PRP is mixed, with some evidence for use in certain conditions and against use in other conditions. [9] [10] [3] It has been investigated for chronic tendinitis, [11] osteoarthritis, [12] in oral surgery, [13] and in plastic surgery. [14]

Elbow tendinitis

A 2022 study from the Journal of Clinical Medicine compared PRP injections to physical therapy. They found that PRP lowered pain scores and increased elbow function significantly. [15] A 2022 study examined the effectiveness of PRP for elbow tendinopathy. They found that PRP was effective and that the concentration of the platelets and healing factors such as epidermal growth factor (EGF) were correlated with success of treatment. [16]

A 2022 meta-analysis examined 26 studies on PRP for elbow tendinopathy. They found that PRP treated patients rated their results significantly better using validated patient rated outcomes measures. [17] A 2021 systematic review by the Cochrane Library examined PRP and autologous whole blood injections and concluded that it was "uncertain" if PRP or autologous whole blood injections improved elbow tendon healing. [18]

A 2018 systematic review and meta-analysis of high quality studies found that PRP was beneficial for treatment of lateral epicondylitis. [19]

Numerous systematic reviews and meta-analyses have found that for elbow tendinopathy, PRP is superior to cortisone injections. [20] [21] [22] [23] [24] It has been shown to have similar [25] or equal [26] [27] effects compared to surgery.

Rotator cuff disease

A 2022 systematic review and meta-analysis showed improved patient rated outcomes in patients with partial rotator cuff tears.  At 8 weeks post injection, they found PRP to be effective. [28] A 2021 prospective study examined the effectiveness of PRP for partial thickness rotator cuff tears. Patients were given 2 separate PRP injections and followed for 2 years.  The study noted:  “No adverse events were seen in any patient. Based on global rating scores positive results were seen in 77.9 % of patients at 6 months, 71.6 % at 1 year, and 68.8 % of patients at 2 years”.  They found PRP most effective in more damaged tendons. [29] A 2021 meta-analysis found that PRP was effective for partial rotator cuff tears but the effects were no longer evident at 1 year. [30]

PRP has been shown to be superior to cortisone injections in several studies. [31] This is especially evident in the longer term. [32] [33]

A 2019 review found it not to be useful in rotator cuff disease. [3] A 2019 meta-analysis found that, for most outcomes in Achilles tendinopathy, PRP treatment did not differ from placebo treatment. [34] A 2018 review found that it may be useful. [19] A 2009 review found few randomized controlled trials that adequately evaluated the safety and efficacy of PRP treatments and concluded that PRP was "a promising, but not proven, treatment option for joint, tendon, ligament, and muscle injuries". [35]

Osteoarthritis

Tentative evidence supports the use of PRP in osteoarthritis (OA) of the knee. [36] [37] A 2019 meta-analysis found that PRP might be more effective in reducing pain and improving function than hyaluronic acid in knee OA. [38]

Dental

A 2010 Cochrane review of use in sinus lifts during dental implant placement found no evidence of benefit. [13]

Other musculoskeletal

A 2014 Cochrane review of musculoskeletal injuries found very weak evidence for a decrease in pain in the short term, and no difference in function in the short, medium or long term. It has not been shown to be useful for bone healing. [39] A 2016 review of bone graft augmentation found only one study reporting a difference in bone augmentation, while four studies found no difference. [40] As compared to other conservative treatments for non-surgical orthopedic illnesses (e.g. steroid injection for plantar fasciitis), evidence does not support the use of PRP as a conservative treatment. [41] A 2018 review found that evidence was lacking for Achilles tendinopathy. [42] A 2019 study conducted an umbrella review that "considered studies that included populations with differing levels of physical activity, including studies on the sporting population (professional and/or recreational athletes) and studies didn't explicitly mention involving a sporting population." This inquiry showed that there is poor quality evidence that PRP offers any clinical benefits for treatment in acute muscle, tendon, and ligament injuries in any population. [43]

Hair loss

Studies have found that PRP is beneficial for alopecia areata [44] and androgenetic alopecia and can be used as an alternative to minoxidil or finasteride. [45] It has been documented to improve hair density and thickness in both genders. [46] A minimum of 3 treatments, once a month for 3 months are recommended, and afterwards a 3-6 month period of continual appointments for maintenance. [47] Factors that determine efficacy include amount of sessions, double versus single centrifugation, age and gender, and where the PRP is inserted. [48]

Larger randomized controlled trials and other high quality studies are recommended to strengthen consensus. [49] [46] [50] [51] Further development of a standardized practice for procedure is also recommended. [44]

Assisted reproduction

PRP obtained from the patient herself can be inoculated into the uterine cavity, since the growth factors it contains could improve endometrial receptivity in cases of refractory endometrium. Different studies have shown that intrauterine inoculation of PRP before embryo transfer can help these women obtain a thicker endometrium and improve their reproductive prognosis. [52] PRP has also been studied for the management of Asherman's Syndrome. [53]

PRP can also be inoculated into the ovary, with the aim of promoting ovarian tissue regeneration. However, this technique is at a more experimental stage. The main applications of PRP in the ovary would be in cases of diminished ovarian reserve or premature ovarian failure. Thus, the ovarian injection of PRP is intended to improve the ovarian function of these patients. [54]

A 2023 retrospective observational study demonstrated PRP's effectiveness in rejuvenating ovarian fertility and viability. 469 women participated in the study with the average age of 41.9 ± 4.3 years. His team's research revealed that the restorative properties present in PRP have to potential to restore ovarian function when used for intraovarian infusions. This study indicates that PRP may work because of the growth factors present in the shot that are able to spur the remaining ovarian stem cells to redevelop and grow stronger. They produced these results by examining "the influence of intraovarian injection of autologous PRP on the levels of E2 [55] and FSH [56] and pregnancy outcome in women treated with PRP who had a history of infertility, hormonal abnormalities, an absence of menstrual cycle, and premature ovarian failure in a single centre." [57]

A 2024 systemic review showed that PRP is beneficial when used as intraovarian injections for women with decreased fertility. When PRP is used for fertility trouble, it has been proven to increase AFC [58] , number of retrieved oocytes [59] , number of cleavage embryos [60] , and improve cancellation rate in women with POR [61] . However the authors highlight that despite the positive results garnered, they are not statistically telling. "Although there was an improvement of baseline hormones (AMH [62] , FSH, and E2) after intraovarian injection of PRP, this improvement failed to reach statistical significance (except the improvement of serum AMH analyzed in quasi-experimental studies)." This study helped to show that PRP still needs to be studied further to truly grasp the full fertility benefits. [63]

Venous ulcers

Venous ulcers are ankle or lower leg wounds that become open and remain that way for weeks to months. [64] A 2024 meta-analysis provided evidence that PRP has a positive effect on the size of ulcers as well as complete healing time for venous ulcers compared to the time with standard treatments. Combining PRP with conventional venous ulcer treatments has shown improved quality of life and healing time. When addressing concerns for this use of PRP, The author said "In terms of safety, the recurrence rate in the PRP group was significantly lower than that in the control group, while the rates of infection and irritative dermatitis showed no significant difference from the control group." PRP is both a safe and effective method for the treatment of venous ulcers. [65]

Diabetic foot ulcers

A 2024 meta-analysis showed that the growth factors present in aPRP are vital in the healing of DFU patients specifically the closure of the ulcers. The author states that “these treatments significantly increase the ulcer healing rate compared to existing conventional treatments.” When using aPRP, DFU patients can expect their ulcer to close better than compared to how they would close with standard treatments. [66]

Adverse effects

Adverse effects have been rarely reported to be low in most trials. A 2017 systematic review of the literature did not report of the types and number of adverse events. [67] Health Canada states PRP treatments harvested from, and given back to, the same person (in a single procedure) was not covered by its initial guidance as the procedure falls under health care provider regulatory bodies (rather than Health Canada). [68] There was weak evidence that suggested that harm occurred at comparable, low rates in treated and untreated people. [69] [18] Similarly, another 2017 review for treating pain on skin graft donor sites found the evidence for benefit was poor. [70]

Composition

Whole blood placed in centrifuge prior to two-stage centrifugation PRP Centrifuge.JPG
Whole blood placed in centrifuge prior to two-stage centrifugation

There are three general categories of preparation of PRP based on its leukocyte and fibrin content: leukocyte-rich PRP (L-PRP), leukocyte reduced PRP (P-PRP; leukocyte reduced or pure PRP), leukocyte platelet-rich fibrin. [7] [71]

The efficacy of certain growth factors in healing various injuries and the concentrations of these growth factors found within PRP are the theoretical basis for the use of PRP in tissue repair. [72] Though not required for the process, The platelets collected in PRP can be activated by the addition of thrombin or calcium chloride, which induces the release of the mentioned factors from alpha granules. The addition of Thrombin or Calcium Chloride is not required as the bodies natural thrombin will activate the cells upon injection. The growth factors and other cytokines present in PRP include: [72] [73] [74] [75]

Manufacturing

PRP is prepared by taking blood from the person, and then putting it through centrifugation designed to separate PRP from platelet-poor plasma and red blood cells. This is usually done by the clinic offering the treatment, using commercially available kits and equipment. [76] The resulting substance varies from person to person and from facility to facility, making it difficult to understand how safe and effective any specific use is. [76] [77]

Society and culture

PRP has received attention in the popular media [78] [79] [80] as a result of its use by athletes. [81] Use in an office setting is not approved by the FDA. [82]

In the 2010s, contentious cosmetic procedures marketed under the name of "vampire facials" grew in popularity, fueled by celebrity endorsement. These "vampire facials" generally center on PRP treatment, and usually (but not always) involve microneedling. [83] [84]

In April 2024, the CDC announced that three women who had been patients at the Albuquerque, New Mexico, VIP Spa had been diagnosed with HIV after getting "vampire facials" there. Another almost 200 former clients and their sexual partners were also tested but were found to not have HIV. No mention was made of any testing for other possible blood-borne infections. [85]

PRP has also been injected into the vagina, in a procedure called "O-shot [86] " or "orgasm shot", with claims that this will improve orgasms. [87] There is no evidence, however, to support these claims. [87] [88]

Doping

Some concern exists as to whether PRP treatments violate anti-doping rules. [72] As of 2010, it was not clear if local injections of PRP could have a systemic impact on circulating cytokine levels, affecting doping tests and whether PRP treatments have systemic anabolic effects or affect performance. [72] In January 2011, the World Anti-Doping Agency removed intramuscular injections of PRP from its prohibitions after determining that there is a "lack of any current evidence concerning the use of these methods for purposes of performance enhancement". [89]

History

In the early 1940s clinicians used extracts of growth factors and cytokines for healing. The term 'platet-rich plasma' was first used in 1954 by Kingsley and in the 1960s the first PRP blood banks were established, becoming popular by the 1970s. [90] In the 1970s PRP was used in the field of hematology, originally for transfusions to treat thrombocytopenia. Ten years later it was used for maxillofacial surgeries. [6] PRP was first used in Italy in 1987 in an open heart surgery procedure. [91] In 2006 PRP was starting to be considered of potential use for both androgenic alopecia and alopecia areata, though research remained mixed. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Anticoagulant</span> Class of drugs

An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.

<span class="mw-page-title-main">Tendinopathy</span> Inflammation of the tendon

Tendinopathy is a type of tendon disorder that results in pain, swelling, and impaired function. The pain is typically worse with movement. It most commonly occurs around the shoulder, elbow, wrist, hip, knee, or ankle.

<span class="mw-page-title-main">Osteoarthritis</span> Form of arthritis caused by degeneration of joints

Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. It is believed to be the fourth leading cause of disability in the world, affecting 1 in 7 adults in the United States alone. The most common symptoms are joint pain and stiffness. Usually the symptoms progress slowly over years. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs, the knee and hip joints, and the joints of the neck and lower back. The symptoms can interfere with work and normal daily activities. Unlike some other types of arthritis, only the joints, not internal organs, are affected.

<span class="mw-page-title-main">Tennis elbow</span> Condition in which the outer part of the elbow becomes sore and tender

Tennis elbow, also known as lateral epicondylitis or enthesopathy of the extensor carpi radialis origin, is an enthesopathy of the origin of the extensor carpi radialis brevis on the lateral epicondyle. The outer part of the elbow becomes painful and tender. The pain may also extend into the back of the forearm. Onset of symptoms is generally gradual, although they can seem sudden and be misinterpreted as an injury. Golfer's elbow is a similar condition that affects the inside of the elbow.

<span class="mw-page-title-main">Achilles tendinitis</span> Medical condition of the ankle and heel

Achilles tendinitis, also known as achilles tendinopathy, occurs when the Achilles tendon, found at the back of the ankle, becomes sore. Achilles tendinopathy is accompanied by alterations in the tendon's structure and mechanical properties. The most common symptoms are pain and swelling around the affected tendon. The pain is typically worse at the start of exercise and decreases thereafter. Stiffness of the ankle may also be present. Onset is generally gradual.

<span class="mw-page-title-main">Rotator cuff tear</span> Shoulder injury

Rotator cuff tendinopathy is a process of senescence. The pathophysiology is mucoid degeneration. Most people develop rotator cuff tendinopathy within their lifetime.

<span class="mw-page-title-main">Joint injection</span> Method of delivering drugs into a joint

In medicine, a joint injection is a procedure used in the treatment of inflammatory joint conditions, such as rheumatoid arthritis, psoriatic arthritis, gout, tendinitis, bursitis, Carpal Tunnel Syndrome, and occasionally osteoarthritis. A hypodermic needle is injected into the affected joint where it delivers a dose of any one of many anti-inflammatory agents, the most common of which are corticosteroids. Hyaluronic acid, because of its high viscosity, is sometimes used to replace bursa fluids. The technique may be used to also withdraw excess fluid from the joint.

Prolotherapy, also called proliferation therapy, is an injection-based treatment used in chronic musculoskeletal conditions. It has been characterised as an alternative medicine practice.

The management of hair loss, includes prevention and treatment of alopecia, baldness, and hair thinning, and regrowth of hair.

<span class="mw-page-title-main">Patellar tendinitis</span> Human disease

Patellar tendinitis, also known as jumper's knee, is an overuse injury of the tendon that straightens the knee. Symptoms include pain in the front of the knee. Typically the pain and tenderness is at the lower part of the kneecap, though the upper part may also be affected. Generally there is no pain when the person is at rest. Complications may include patellar tendon rupture.

<span class="mw-page-title-main">Blood-spinning</span> Medical procedure

Blood-spinning is a medical procedure used to shorten the healing time of an injury. Small samples of the patient's blood are taken and spun in a centrifuge, allowing platelets and blood plasma to be isolated from other blood components. The platelets and plasma are then combined forming platelet-rich plasma (PRP), which has high concentrations of natural growth factors. The PRP sample can then be injected into the patient's injury, which may help reduce pain and improve recovery speeds.

<span class="mw-page-title-main">Pattern hair loss</span> Medical condition

Pattern hair loss is a hair loss condition that primarily affects the top and front of the scalp. In male-pattern hair loss (MPHL), the hair loss typically presents itself as either a receding front hairline, loss of hair on the crown (vertex) of the scalp, or a combination of both. Female-pattern hair loss (FPHL) typically presents as a diffuse thinning of the hair across the entire scalp.

<span class="mw-page-title-main">Extracorporeal shockwave therapy</span> Ultrasonic, non-invasive, outpatient treatment

Extracorporeal shockwave therapy (ESWT) is a treatment using powerful acoustic pulses which is mostly used to treat kidney stones and in physical therapy and orthopedics.

Autologous blood therapy, also known as autologous blood injection or autohemotherapy, comprises certain types of hemotherapy using a person's own blood. There are several kinds, the original belonging only to traditional medicine, alternative medicine, and some newer kind of medicine under investigation. The original, unscientific form is "the immediate intramuscular or subcutaneous reinjection of freshly drawn autologous blood". It was used in the early 20th century, when some physicians believed that it had efficacy and a logical mechanism of action; it was abandoned as advancing science made clear that it lacked those.

<span class="mw-page-title-main">Low-level laser therapy</span> Treatment using irradiation with light of low power intensity

Low-level laser therapy (LLLT), cold laser therapy, photobiomodulation (PBM) or red light therapy is a form of medicine that applies low-level (low-power) lasers or light-emitting diodes (LEDs) to the surface of the body. Whereas high-power lasers are used in laser medicine to cut or destroy tissue, it is claimed that application of low-power lasers relieves pain or stimulates and enhances cell function. The effects appear to be limited to a specified set of wavelengths and new research has demonstrated effectiveness at myopia control. Several such devices are cleared by the United States Food and Drug Administration (FDA), and research shows potential for treating a range of medical problems including rheumatoid arthritis and oral mucositis.

Platelet-Poor Plasma (PPP) is blood plasma with very low number of platelets (< 10 X 103/μL). Traditionally, PPP was recommended for use in platelet aggregation studies to both adjust the platelet-rich plasma concentration, and to serve as a control. PPP may have elevated levels of fibrinogen, which has the ability to form a fibrin-rich clot once activated. Wound healing requires cell migration and attachment, which is facilitated by this fibrin clot.

<span class="mw-page-title-main">Collagen induction therapy</span> Cosmetic procedure

Collagen induction therapy (CIT), also known as microneedling, dermarolling, or skin needling, is a cosmetic procedure that involves repeatedly puncturing the skin with tiny, sterile needles. CIT should be separated from other contexts in which microneedling devices are used on the skin.

Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRP where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue and is used as a tissue-engineering scaffold in oral and maxillofacial surgeries. PRF falls under FDA Product Code KST, labeling it as a blood draw/Hematology product classifying it as 510(k) exempt.

Plasma needling is a minimally invasive aesthetic medical procedure purported to rejuvenate skin, minimize the appearance of hypertrophic and hypotrophic scars and stretchmarks, and reduce pattern hair loss through multimodal physical and biochemical cellular stimulation. It is a combination of classical medical micro-needling by Dermaroller or DermaPen. Both are used in Collagen induction therapy and PRP. The latter is used in Prolotherapy as well as in the Vampire facelift. The effects on fibroblasts, cells, and micro-needling stem cells are published in scientific publications regarding micro-needling, and the injection of PRP, has also been tested as a combined treatment.

James H-C. Wang is a Chinese American orthopedic biomechanist and academic. Currently, he is a Professor at the Departments of Orthopaedic Surgery, Bioengineering, and PM&R at the University of Pittsburgh. In addition, he is a Faculty Member at the McGowan Institute for Regenerative Medicine.

References

  1. ↑ Xu Q, Chen J, Cheng L (July 2019). "Comparison of platelet rich plasma and corticosteroids in the management of lateral epicondylitis: A meta-analysis of randomized controlled trials". International Journal of Surgery. 67: 37–46. doi: 10.1016/j.ijsu.2019.05.003 . PMID   31128316.
  2. ↑ Belk JW, Kraeutler MJ, Houck DA, Goodrich JA, Dragoo JL, McCarty EC (January 2021). "Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials". The American Journal of Sports Medicine. 49 (1): 249–260. doi:10.1177/0363546520909397. PMID   32302218. S2CID   215809299.
  3. 1 2 3 Hurley ET, Hannon CP, Pauzenberger L, Fat DL, Moran CJ, Mullett H (May 2019). "Nonoperative Treatment of Rotator Cuff Disease With Platelet-Rich Plasma: A Systematic Review of Randomized Controlled Trials". Arthroscopy. 35 (5): 1584–1591. doi:10.1016/j.arthro.2018.10.115. PMID   31000394. S2CID   122575307.
  4. ↑ Smith PA (April 2016). "Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial". The American Journal of Sports Medicine. 44 (4): 884–891. doi:10.1177/0363546515624678. PMID   26831629. S2CID   42338794.
  5. ↑ de la Portilla F, Segura-Sampedro JJ, Reyes-Díaz ML, Maestre MV, Cabrera AM, Jimenez-Rodríguez RM, et al. (November 2017). "Treatment of transsphincteric fistula-in-ano with growth factors from autologous platelets: results of a phase II clinical trial". International Journal of Colorectal Disease. 32 (11): 1545–1550. doi:10.1007/s00384-017-2866-9. PMID   28755243. S2CID   23285036.
  6. 1 2 3 Alves R, Grimalt R (January 2018). "A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification". Skin Appendage Disorders. 4 (1): 18–24. doi: 10.1159/000477353 . PMC   5806188 . PMID   29457008.
  7. 1 2 Pavlovic V, Ciric M, Jovanovic V, Stojanovic P (2016). "Platelet Rich Plasma: a short overview of certain bioactive components". Open Medicine. 11 (1): 242–247. doi:10.1515/med-2016-0048. PMC   5329835 . PMID   28352802.
  8. ↑ Lang S, Loibl M, Herrmann M (2018). "Platelet-Rich Plasma in Tissue Engineering: Hype and Hope". European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes. 59 (3–4): 265–275. doi:10.1159/000492415. PMID   30244245. S2CID   52344177.
  9. ↑ Mohammed W, Farah S, Nassiri M, McKenna J (2020). "Therapeutic efficacy of platelet-rich plasma injection compared to corticosteroid injection in plantar fasciitis: A systematic review and meta-analysis". Journal of Orthopaedics. 22: 124–134. doi:10.1016/j.jor.2020.03.053. PMC   7177161 . PMID   32336895.
  10. ↑ Lin MT, Wei KC, Wu CH (March 2020). "Effectiveness of Platelet-Rich Plasma Injection in Rotator Cuff Tendinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Diagnostics. 10 (4): 189. doi: 10.3390/diagnostics10040189 . PMC   7235747 . PMID   32231127.
  11. ↑ Mishra A, Woodall J, Vieira A (January 2009). "Treatment of tendon and muscle using platelet-rich plasma". Clinics in Sports Medicine. 28 (1): 113–125. doi:10.1016/j.csm.2008.08.007. PMID   19064169.
  12. ↑ Andia I, Sánchez M, Maffulli N (January 2012). "Joint pathology and platelet-rich plasma therapies". Expert Opinion on Biological Therapy. 12 (1): 7–22. doi:10.1517/14712598.2012.632765. PMID   22171664. S2CID   39322743.
  13. 1 2 Esposito M, Grusovin MG, Rees J, Karasoulos D, Felice P, Alissa R, et al. (Spring 2010). "Effectiveness of sinus lift procedures for dental implant rehabilitation: a Cochrane systematic review". European Journal of Oral Implantology. 3 (1): 7–26. PMID   20467595.
  14. ↑ Por YC, Shi L, Samuel M, Song C, Yeow VK (May 2009). "Use of tissue sealants in face-lifts: a metaanalysis". Aesthetic Plastic Surgery. 33 (3): 336–339. doi:10.1007/s00266-008-9280-1. PMID   19089492. S2CID   26761928.
  15. ↑ Annaniemi JA, Pere J, Giordano S (December 2022). "Platelet-Rich Plasma Injections Decrease the Need for Any Surgical Procedure for Chronic Epicondylitis versus Conservative Treatment-A Comparative Study with Long-Term Follow-Up". Journal of Clinical Medicine. 12 (1): 102. doi: 10.3390/jcm12010102 . PMC   9821066 . PMID   36614903.
  16. ↑ Dejnek M, Moreira H, Płaczkowska S, Barg E, Reichert P, Królikowska A (June 2022). "Effectiveness of Lateral Elbow Tendinopathy Treatment Depends on the Content of Biologically Active Compounds in Autologous Platelet-Rich Plasma". Journal of Clinical Medicine. 11 (13): 3687. doi: 10.3390/jcm11133687 . PMC   9267331 . PMID   35806972.
  17. ↑ Paramanantham M, Seenappa H, Venkataraman S, Shanthappa AH (March 2022). "Functional Outcome of Platelet-Rich Plasma (PRP) Intra-lesional Injection for Tennis Elbow - A Prospective Cohort Study". Cureus. 14 (3): e22974. doi: 10.7759/cureus.22974 . PMC   8990042 . PMID   35415041.
  18. 1 2 Karjalainen TV, Silagy M, O'Bryan E, Johnston RV, Cyril S, Buchbinder R (September 2021). "Autologous blood and platelet-rich plasma injection therapy for lateral elbow pain". The Cochrane Database of Systematic Reviews. 2021 (9): CD010951. doi:10.1002/14651858.CD010951.pub2. PMC   8481072 . PMID   34590307.
  19. 1 2 Chen X, Jones IA, Park C, Vangsness CT (July 2018). "The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias Assessment". The American Journal of Sports Medicine. 46 (8): 2020–2032. doi:10.1177/0363546517743746. PMC   6339617 . PMID   29268037.
  20. ↑ Klifto KM, Colbert SH, Richard MJ, Anakwenze OA, Ruch DS, Klifto CS (May 2022). "Platelet-rich plasma vs. corticosteroid injections for the treatment of recalcitrant lateral epicondylitis: a cost-effectiveness Markov decision analysis". Journal of Shoulder and Elbow Surgery. 31 (5): 991–1004. doi:10.1016/j.jse.2021.12.010. PMID   35031496. S2CID   245900117.
  21. ↑ Kemp JA, Olson MA, Tao MA, Burcal CJ (June 2021). "Platelet-Rich Plasma versus Corticosteroid Injection for the Treatment of Lateral Epicondylitis: A Systematic Review of Systematic Reviews". International Journal of Sports Physical Therapy. 16 (3): 597–605. doi:10.26603/001c.24148. PMC   8169032 . PMID   34123513.
  22. ↑ Li A, Wang H, Yu Z, Zhang G, Feng S, Liu L, et al. (December 2019). "Platelet-rich plasma vs corticosteroids for elbow epicondylitis: A systematic review and meta-analysis". Medicine. 98 (51): e18358. doi:10.1097/MD.0000000000018358. PMC   6940118 . PMID   31860992.
  23. ↑ Houck DA, Kraeutler MJ, Thornton LB, McCarty EC, Bravman JT (March 2019). "Treatment of Lateral Epicondylitis With Autologous Blood, Platelet-Rich Plasma, or Corticosteroid Injections: A Systematic Review of Overlapping Meta-analyses". Orthopaedic Journal of Sports Medicine. 7 (3): 2325967119831052. doi:10.1177/2325967119831052. PMC   6419259 . PMID   30899764.
  24. ↑ Arirachakaran A, Sukthuayat A, Sisayanarane T, Laoratanavoraphong S, Kanchanatawan W, Kongtharvonskul J (June 2016). "Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: systematic review and network meta-analysis". Journal of Orthopaedics and Traumatology. 17 (2): 101–112. doi:10.1007/s10195-015-0376-5. PMC   4882297 . PMID   26362783.
  25. ↑ Hardy R, Tori A, Fuchs H, Larson T, Brand J, Monroe E (November 2021). "To Improve Pain and Function, Platelet-Rich Plasma Injections May Be an Alternative to Surgery for Treating Lateral Epicondylitis: A Systematic Review". Arthroscopy. 37 (11): 3360–3367. doi:10.1016/j.arthro.2021.04.043. PMID   33957212. S2CID   233982749.
  26. ↑ Kim CH, Park YB, Lee JS, Jung HS (February 2022). "Platelet-rich plasma injection vs. operative treatment for lateral elbow tendinosis: a systematic review and meta-analysis". Journal of Shoulder and Elbow Surgery. 31 (2): 428–436. doi:10.1016/j.jse.2021.09.008. PMID   34656779. S2CID   239019467.
  27. ↑ Boden AL, Scott MT, Dalwadi PP, Mautner K, Mason RA, Gottschalk MB (January 2019). "Platelet-rich plasma versus Tenex in the treatment of medial and lateral epicondylitis". Journal of Shoulder and Elbow Surgery. 28 (1): 112–119. doi:10.1016/j.jse.2018.08.032. PMID   30551782. S2CID   54632733.
  28. ↑ Zhu P, Wang Z, Li H, Cai Y (September 2022). "Platelet-Rich Plasma Injection in Non-Operative Treatment of Partial-Thickness Rotator Cuff Tears: A Systematic Review and Meta-Analysis". Journal of Rehabilitation Medicine. 54: jrm00312. doi:10.2340/jrm.v54.1434. PMC   9495266 . PMID   35892292.
  29. ↑ Prodromos CC, Finkle S, Prodromos A, Chen JL, Schwartz A, Wathen L (May 2021). "Treatment of Rotator Cuff Tears with platelet rich plasma: a prospective study with 2 year follow-up". BMC Musculoskeletal Disorders. 22 (1): 499. doi: 10.1186/s12891-021-04288-4 . PMC   8164813 . PMID   34051761.
  30. ↑ Xiang XN, Deng J, Liu Y, Yu X, Cheng B, He HC (December 2021). "Conservative treatment of partial-thickness rotator cuff tears and tendinopathy with platelet-rich plasma: A systematic review and meta-analysis". Clinical Rehabilitation. 35 (12): 1661–1673. doi:10.1177/02692155211011944. PMID   33896214. S2CID   229348580.
  31. ↑ Kwong CA, Woodmass JM, Gusnowski EM, Bois AJ, Leblanc J, More KD, et al. (February 2021). "Platelet-Rich Plasma in Patients With Partial-Thickness Rotator Cuff Tears or Tendinopathy Leads to Significantly Improved Short-Term Pain Relief and Function Compared With Corticosteroid Injection: A Double-Blind Randomized Controlled Trial". Arthroscopy. 37 (2): 510–517. doi:10.1016/j.arthro.2020.10.037. PMID   33127554. S2CID   226217973.
  32. ↑ Kim SJ, Kim EK, Kim SJ, Song DH (January 2018). "Effects of bone marrow aspirate concentrate and platelet-rich plasma on patients with partial tear of the rotator cuff tendon". Journal of Orthopaedic Surgery and Research. 13 (1): 1. doi: 10.1186/s13018-017-0693-x . PMC   5753487 . PMID   29298726.
  33. ↑ Giovannetti de Sanctis E, Franceschetti E, De Dona F, Palumbo A, Paciotti M, Franceschi F (December 2020). "The Efficacy of Injections for Partial Rotator Cuff Tears: A Systematic Review". Journal of Clinical Medicine. 10 (1): 51. doi: 10.3390/jcm10010051 . PMC   7795404 . PMID   33375716.
  34. ↑ Liu CJ, Yu KL, Bai JB, Tian DH, Liu GL (April 2019). "Platelet-rich plasma injection for the treatment of chronic Achilles tendinopathy: A meta-analysis". Medicine. 98 (16): e15278. doi:10.1097/MD.0000000000015278. PMC   6494278 . PMID   31008973.
  35. ↑ Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA (November 2009). "Platelet-rich plasma: from basic science to clinical applications". The American Journal of Sports Medicine. 37 (11): 2259–2272. doi:10.1177/0363546509349921. PMID   19875361. S2CID   5914979.
  36. ↑ Dai WL, Zhou AG, Zhang H, Zhang J (March 2017). "Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials". Arthroscopy. 33 (3): 659–670.e1. doi: 10.1016/j.arthro.2016.09.024 . PMID   28012636.
  37. ↑ Shen L, Yuan T, Chen S, Xie X, Zhang C (January 2017). "The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials". Journal of Orthopaedic Surgery and Research. 12 (1): 16. doi: 10.1186/s13018-017-0521-3 . PMC   5260061 . PMID   28115016.
  38. ↑ Han Y, Huang H, Pan J, Lin J, Zeng L, Liang G, et al. (July 2019). "Meta-analysis Comparing Platelet-Rich Plasma vs Hyaluronic Acid Injection in Patients with Knee Osteoarthritis". Pain Medicine. 20 (7): 1418–1429. doi:10.1093/pm/pnz011. PMC   6611633 . PMID   30849177.
  39. ↑ Griffin XL, Smith CM, Costa ML (February 2009). "The clinical use of platelet-rich plasma in the promotion of bone healing: a systematic review". Injury. 40 (2): 158–162. doi:10.1016/j.injury.2008.06.025. PMID   19084836.
  40. ↑ Pocaterra A, Caruso S, Bernardi S, Scagnoli L, Continenza MA, Gatto R (August 2016). "Effectiveness of platelet-rich plasma as an adjunctive material to bone graft: a systematic review and meta-analysis of randomized controlled clinical trials". International Journal of Oral and Maxillofacial Surgery. 45 (8): 1027–1034. doi:10.1016/j.ijom.2016.02.012. PMID   26987695.
  41. ↑ Franchini M, Cruciani M, Mengoli C, Marano G, Pupella S, Veropalumbo E, et al. (November 2018). "Efficacy of platelet-rich plasma as conservative treatment in orthopaedics: a systematic review and meta-analysis". Blood Transfusion = Trasfusione del Sangue. 16 (6): 502–513. doi:10.2450/2018.0111-18. PMC   6214820 . PMID   30201082.
  42. ↑ Zhang YJ, Xu SZ, Gu PC, Du JY, Cai YZ, Zhang C, et al. (August 2018). "Is Platelet-rich Plasma Injection Effective for Chronic Achilles Tendinopathy? A Meta-analysis". Clinical Orthopaedics and Related Research. 476 (8): 1633–1641. doi:10.1007/s11999.0000000000000258. PMC   6259774 . PMID   29601383.
  43. ↑ Cruciani M, Franchini M, Mengoli C, Marano G, Pati I, Masiello F, et al. (November 2019). "Platelet-rich plasma for sports-related muscle, tendon and ligament injuries: an umbrella review". Blood Transfusion = Trasfusione del Sangue. 17 (6): 465–478. doi:10.2450/2019.0274-19. PMC   6917536 . PMID   31846610.
  44. 1 2 Tejapira K, Yongpisarn T, Sakpuwadol N, Suchonwanit P (2022-11-24). "Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review". Frontiers in Medicine. 9. Frontiers Media SA: 1058431. doi: 10.3389/fmed.2022.1058431 . PMC   9731377 . PMID   36507528.
  45. ↑ Gentile P, Garcovich S (April 2020). "Systematic Review of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared with Minoxidil®, Finasteride®, and Adult Stem Cell-Based Therapy". International Journal of Molecular Sciences. 21 (8). MDPI AG: 2702. doi: 10.3390/ijms21082702 . PMC   7216252 . PMID   32295047.
  46. 1 2 Evans AG, Mwangi JM, Pope RW, Ivanic MG, Botros MA, Glassman GE, et al. (February 2022). "Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis". The Journal of Dermatological Treatment. 33 (1). Informa UK Limited: 498–511. doi:10.1080/09546634.2020.1770171. PMID   32410524. S2CID   218648227.
  47. ↑ Gupta AK, Cole J, Deutsch DP, Everts PA, Niedbalski RP, Panchaprateep R, et al. (October 2019). "Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia". Dermatologic Surgery. 45 (10). Ovid Technologies (Wolters Kluwer Health): 1262–1273. doi:10.1097/dss.0000000000001894. PMID   30882509. S2CID   81980415.
  48. ↑ Gupta AK, Bamimore M (September 2022). "Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study". Journal of Drugs in Dermatology. 21 (9). SanovaWorks: 943–952. doi:10.36849/jdd.6948. PMID   36074501. S2CID   252120370.
  49. ↑ Gupta AK, Bamimore MA, Foley KA (February 2022). "Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality". The Journal of Dermatological Treatment. 33 (1). Informa UK Limited: 62–72. doi:10.1080/09546634.2020.1749547. PMID   32250713. S2CID   215405183.
  50. ↑ Oth O, Stene JJ, Glineur R, Vujovic A (May 2018). "[Injection of PRP (Platelet-rich plasma) as a treatment for androgenetic alopecia : a systematic review of the literature]". Revue Medicale de Bruxelles. 39 (5). AMUB/Revue Médicale de Bruxelles: 438–446. doi: 10.30637/2018.17-056 . PMID   29869472.
  51. ↑ Valente Duarte de Sousa IC, Tosti A (May 2013). "New investigational drugs for androgenetic alopecia". Expert Opinion on Investigational Drugs. 22 (5): 573–589. doi:10.1517/13543784.2013.784743. PMID   23550739. S2CID   21653303.
  52. ↑ Dogra Y, Singh N, Vanamail P. Autologous platelet-rich plasma optimizes endometrial thickness and pregnancy outcomes in women with refractory thin endometrium of varied aetiology during fresh and frozen-thawed embryo transfer cycles. JBRA Assist Reprod. 2022 Jan 17;26(1):13-21. doi: 10.5935/1518-0557.20210037.
  53. ↑ Aghajanova L, Cedars MI, Huddleston HG. Platelet-rich plasma in the management of Asherman syndrome: case report. J Assist Reprod Genet. 2018 May;35(5):771-775. doi: 10.1007/s10815-018-1135-3
  54. ↑ Fraidakis M, Giannakakis G, Anifantaki A, Skouradaki M, Tsakoumi P, Bitzopoulou P, Kourpa S, Zervakis A, Kakouri P. Intraovarian Platelet-Rich Plasma Injections: Safety and Thoughts on Efficacy Based on a Single Centre Experience With 469 Women. Cureus. 2023 May 7;15(5):e38674. doi: 10.7759/cureus.38674.
  55. ↑ "Estradiol", Wikipedia, 2024-03-08, retrieved 2024-03-21
  56. ↑ "Follicle-stimulating hormone", Wikipedia, 2024-03-12, retrieved 2024-03-21
  57. ↑ Fraidakis M, Giannakakis G, Anifantaki A, Skouradaki M, Tsakoumi P, Bitzopoulou P, et al. (2023-05-07). "Intraovarian Platelet-Rich Plasma Injections: Safety and Thoughts on Efficacy Based on a Single Centre Experience With 469 Women". Cureus. 15 (5). doi: 10.7759/cureus.38674 . ISSN   2168-8184. PMC   10243509 . PMID   37288228.
  58. ↑ "Antral follicle", Wikipedia, 2023-12-23, retrieved 2024-03-26
  59. ↑ "Oocyte", Wikipedia, 2024-03-09, retrieved 2024-03-26
  60. ↑ "Cleavage (embryo)", Wikipedia, 2024-02-09, retrieved 2024-03-26
  61. ↑ "Poor ovarian reserve", Wikipedia, 2024-03-08, retrieved 2024-03-26
  62. ↑ "Anti-Müllerian hormone", Wikipedia, 2024-02-07, retrieved 2024-03-26
  63. ↑ Maged AM, Mohsen RA, Salah N, Ragab WS (2024-01-27). "The value of intraovarian autologous platelet rich plasma in women with poor ovarian reserve or ovarian insufficiency: a systematic review and meta-analysis". BMC Pregnancy and Childbirth. 24 (1): 85. doi: 10.1186/s12884-024-06251-2 . ISSN   1471-2393. PMC   10821562 . PMID   38280991.
  64. ↑ "Venous Ulcer Symptoms and Treatment | UPMC". UPMC | Life Changing Medicine. Retrieved 2024-04-25.
  65. ↑ Hu Z, Wang S, Yang H, Xv H, Shan B, Lin L, et al. (February 2024). "Efficacy and safety of platelet-rich plasma in the treatment of venous ulcers: A systematic review and meta-analysis of randomized controlled trials". International Wound Journal. 21 (2): e14736. doi:10.1111/iwj.14736. PMC   10869651 . PMID   38361238.
  66. ↑ Ruiz-Muñoz M, Martinez-Barrios FJ, Fernandez-Torres R, Lopezosa-Reca E, Marchena-Rodriguez A (February 2024). "Autologous platelet-rich plasma (APRP) in diabetes foot disease: a meta-analysis". Journal of Diabetes and Its Complications. 38 (2): 108690. doi:10.1016/j.jdiacomp.2024.108690. PMID   38278034.
  67. ↑ Frautschi RS, Hashem AM, Halasa B, Cakmakoglu C, Zins JE (March 2017). "Current Evidence for Clinical Efficacy of Platelet Rich Plasma in Aesthetic Surgery: A Systematic Review". Aesthetic Surgery Journal. 37 (3): 353–362. doi: 10.1093/asj/sjw178 . PMID   28207031.
  68. ↑ "Health Canada clarifies position on Platelet Rich Plasma treatments". Health Canada. 26 July 2019. Retrieved 7 January 2020.
  69. ↑ Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC (April 2014). "Platelet-rich therapies for musculoskeletal soft tissue injuries". The Cochrane Database of Systematic Reviews. 2014 (4): CD010071. doi:10.1002/14651858.CD010071.pub3. PMC   6464921 . PMID   24782334.
  70. ↑ Sinha S, Schreiner AJ, Biernaskie J, Nickerson D, Gabriel VA (November 2017). "Treating pain on skin graft donor sites: Review and clinical recommendations". The Journal of Trauma and Acute Care Surgery. 83 (5): 954–964. doi:10.1097/TA.0000000000001615. PMID   28598907. S2CID   44520644.
  71. ↑ Bielecki T, Dohan Ehrenfest DM, Everts PA, Wiczkowski A (June 2012). "The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives". Current Pharmaceutical Biotechnology. 13 (7): 1153–1162. doi:10.2174/138920112800624373. PMID   21740376.
  72. 1 2 3 4 Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F (October 2010). "Platelet-rich plasma in muscle healing". American Journal of Physical Medicine & Rehabilitation. 89 (10): 854–861. doi:10.1097/PHM.0b013e3181f1c1c7. PMID   20855985.
  73. ↑ Yu W, Wang J, Yin J (April 2011). "Platelet-rich plasma: a promising product for treatment of peripheral nerve regeneration after nerve injury". The International Journal of Neuroscience. 121 (4): 176–180. doi:10.3109/00207454.2010.544432. PMID   21244302. S2CID   26837842.
  74. ↑ Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, et al. (July 1998). "Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation". Thrombosis and Haemostasis. 80 (1): 171–175. doi:10.1055/s-0037-1615158. PMID   9684805. S2CID   795299.
  75. ↑ Custo S, Baron B, Felice A, Seria E (5 July 2022). "A comparative profile of total protein and six angiogenically-active growth factors in three platelet products". GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW. 11 (Doc06): Doc06. doi:10.3205/iprs000167. PMC   9284722 . PMID   35909816.
  76. 1 2 Dhurat R, Sukesh M (2014). "Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective". Journal of Cutaneous and Aesthetic Surgery. 7 (4): 189–197. doi: 10.4103/0974-2077.150734 . PMC   4338460 . PMID   25722595.
  77. ↑ Kanchanatawan W, Arirachakaran A, Chaijenkij K, Prasathaporn N, Boonard M, Piyapittayanun P, et al. (May 2016). "Short-term outcomes of platelet-rich plasma injection for treatment of osteoarthritis of the knee". Knee Surgery, Sports Traumatology, Arthroscopy. 24 (5): 1665–1677. doi:10.1007/s00167-015-3784-4. PMID   26387122. S2CID   35221300.
  78. ↑ Schwarz A (2009-02-16). "A Promising Treatment for Athletes, in Blood". The New York Times . New York.
  79. ↑ Kolata G (2010-01-12). "Popular Blood Therapy May Not Work". The New York Times .
  80. ↑ Reynolds G (2011-01-26). "Phys Ed: Does Platelet-Rich Plasma Therapy Really Work?". The New York Times.
  81. ↑ Storrs C (2009-12-18). "Is Platelet-Rich Plasma an Effective Healing Therapy?". Scientific American .
  82. ↑ Beitzel K, Allen D, Apostolakos J, Russell RP, McCarthy MB, Gallo GJ, et al. (February 2015). "US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine". The Journal of Knee Surgery. 28 (1): 29–34. doi: 10.1055/s-0034-1390030 . PMID   25268794.
  83. ↑ Georgiou A (14 September 2018). "What is a vampire facial?". Newsweek. Retrieved 29 March 2019.
  84. ↑ "What it's really like to get the infamous vampire facial". The Independent. 28 February 2018. Retrieved 29 March 2019.
  85. ↑ St John A (2024-04-29). "'Vampire facials' were linked to cases of HIV. Here's what to know about the beauty treatment". Associated Press . Retrieved 2024-04-29.
  86. ↑ "O Shot in San Diego". The Independent. 28 February 2023. Retrieved 17 January 2023.
  87. 1 2 Osborne H (8 July 2016). "Injecting blood plasma into your clitoris for $2,500 won't give you with better orgasms". International Business Times UK. Retrieved 1 October 2018.
  88. ↑ Goodman MP (2016). Female Genital Plastic and Cosmetic Surgery. John Wiley & Sons. p. PT391. ISBN   978-1-118-84848-7. There is presently no information in peer reviewed literature.
  89. ↑ "World Anti-Doping Agency announces changes to Prohibited List". Irish Medical Times . 2011-01-10.
  90. ↑ Mościcka P, Przylipiak A (September 2021). "History of autologous platelet-rich plasma: A short review". Journal of Cosmetic Dermatology. 20 (9). Wiley: 2712–2714. doi: 10.1111/jocd.14326 . PMC   9291029 . PMID   34214233.
  91. ↑ Ferrari M, Zia S, Valbonesi M, Henriquet F, Venere G, Spagnolo S, Grasso MA, Panzani I. A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 1987 Jan;10(1):47-50. PMID 3570542
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.